{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:05:10Z","timestamp":1790255110621,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009139","name":"German Centre for Infection Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005624","name":"Hannover Medical School","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"German Cancer Aid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner Fresenius Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omton.2026.201265","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T06:40:50Z","timestamp":1781160050000},"page":"201265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Next-generation LMP2A-targeting TCR-recombinant T cells with inducible IL-18 expression to treat EBV-associated malignancies"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0112-967X","authenticated-orcid":false,"given":"Agnes","family":"Bonifacius","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Mausberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Floegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Christina","family":"Dragon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Tischer-Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Stoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pegah","family":"Rahmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Spieler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Fernanda","family":"Lammoglia Cobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Halenius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinrich","family":"Abken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Blasczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Nerreter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hudecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Schambach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Hansmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Maecker-Kolhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8378-3298","authenticated-orcid":false,"given":"Britta","family":"Eiz-Vesper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201265_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/931952","article-title":"Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders","volume":"2012","author":"Martorelli","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.omton.2026.201265_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2014.84","article-title":"Epstein-Barr virus latent genes","volume":"47","author":"Kang","year":"2015","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.omton.2026.201265_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3389\/fonc.2018.00265","article-title":"Epstein-Barr Virus-Associated Malignancies: Roles of Viral Oncoproteins in Carcinogenesis","volume":"8","author":"El-Sharkawy","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2026.201265_bib4","first-page":"151","article-title":"EBV Persistence--Introducing the Virus","volume":"390","author":"Thorley-Lawson","year":"2015","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.omton.2026.201265_bib5","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3389\/fonc.2019.00713","article-title":"The Global Landscape of EBV-Associated Tumors","volume":"9","author":"Shannon-Lowe","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2026.201265_bib6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/TP.0b013e318277e344","article-title":"Characteristics of early and late PTLD development in pediatric solid organ transplant recipients","volume":"95","author":"Schober","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.omton.2026.201265_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13652","article-title":"Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Allen","year":"2019","journal-title":"Clin. Transplant."},{"key":"10.1016\/j.omton.2026.201265_bib8","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2015-05-615872","article-title":"How I treat posttransplant lymphoproliferative disorders","volume":"126","author":"Dierickx","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201265_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1290059","article-title":"Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation","volume":"14","author":"O\u2019Reilly","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201265_bib10","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s12325-022-02383-z","article-title":"Expert Consensus on the Characteristics of Patients with Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV(+) PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study","volume":"40","author":"Chaganti","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.omton.2026.201265_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41409-019-0548-7","article-title":"Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities","volume":"55","author":"Al Hamed","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201265_bib12","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood.2023020075","article-title":"How I treat posttransplant lymphoproliferative disorder","volume":"142","author":"Amengual","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201265_bib13","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3109\/10428194.2014.966242","article-title":"Occurrence and prognostic relevance of CD30 expression in post-transplant lymphoproliferative disorders","volume":"56","author":"Vase","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.omton.2026.201265_bib14","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation","volume":"130","author":"Prockop","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omton.2026.201265_bib15","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1182\/bloodadvances.2022007103","article-title":"Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant","volume":"6","author":"Jiang","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201265_bib16","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1078-0432.CCR-22-2415","article-title":"Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting","volume":"29","author":"Pfeiffer","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201265_bib17","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163548","article-title":"Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors","volume":"133","author":"Bonifacius","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omton.2026.201265_bib18","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201265_bib19","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S1470-2045(23)00649-6","volume":"25","author":"Mahadeo","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201265_bib20","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201265_bib21","doi-asserted-by":"crossref","first-page":"11149","DOI":"10.1002\/cam4.5698","article-title":"Role of tumor microenvironment in cancer progression and therapeutic strategy","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.omton.2026.201265_bib22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41416-018-0327-z","article-title":"The clinical role of the TME in solid cancer","volume":"120","author":"Giraldo","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omton.2026.201265_bib23","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/bjh.18828","article-title":"Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed\/refractory solid organ transplant-related PTLD","volume":"202","author":"McKenna","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2026.201265_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5500\/wjt.v10.i2.29","article-title":"Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches","volume":"10","author":"Abbas","year":"2020","journal-title":"World J. Transplant."},{"key":"10.1016\/j.omton.2026.201265_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1086433","article-title":"Non-viral TRAC-knocked-in CD19(KI)CAR-T and gp350(KI)CAR-T cells tested against Burkitt lymphomas with type 1 or 2 EBV infection: In vivo cellular dynamics and potency","volume":"14","author":"Braun","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201265_bib26","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","article-title":"CAR T Cells Releasing IL-18 Convert to T-Bet(high) FoxO1(low) Effectors that Exhibit Augmented Activity against Advanced Solid Tumors","volume":"21","author":"Chmielewski","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.omton.2026.201265_bib27","doi-asserted-by":"crossref","first-page":"e000736","DOI":"10.1136\/jitc-2020-000736","article-title":"CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B\u221735 control Epstein-Barr virus-associated lymphoproliferation","volume":"8","author":"Dragon","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201265_bib28","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201265_bib29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1099\/0022-1317-76-1-139","article-title":"Sequence polymorphism in the Epstein-Barr virus latent membrane protein (LMP)-2 gene","volume":"76","author":"Busson","year":"1995","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.omton.2026.201265_bib30","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.1128\/jvi.67.12.7428-7435.1993","article-title":"HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2","volume":"67","author":"Lee","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201265_bib31","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/tan.13811","article-title":"Common, intermediate and well-documented HLA alleles in world populations: CIWD version 3.0.0","volume":"95","author":"Hurley","year":"2020","journal-title":"HLA"},{"key":"10.1016\/j.omton.2026.201265_bib32","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jcyt.2022.03.005","article-title":"Rapid single-cell identification of Epstein-Barr virus-specific T-cell receptors for cellular therapy","volume":"24","author":"Lammoglia Cobo","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omton.2026.201265_bib33","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1016\/j.ymthe.2024.05.013","article-title":"Granzyme B-activated IL18 potentiates alphabeta and gammadelta CAR T cell immunotherapy in a tumor-dependent manner","volume":"32","author":"Hull","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201265_bib34","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201265_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1289313","article-title":"Mechanisms of T cell evasion by Epstein-Barr virus and implications for tumor survival","volume":"14","author":"Sausen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201265_bib36","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nrclinonc.2012.111","article-title":"T-cell therapy in the treatment of post-transplant lymphoproliferative disease","volume":"9","author":"Bollard","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201265_bib37","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1182\/blood-2016-03-707836","article-title":"Targeting Epstein-Barr virus-transformed B lymphoblastoid cells using antibodies with T-cell receptor-like specificities","volume":"128","author":"Lai","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201265_bib38","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1084\/jem.20070256","article-title":"A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates","volume":"204","author":"Hislop","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omton.2026.201265_bib39","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.4049\/jimmunol.0803218","article-title":"Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation","volume":"182","author":"Horst","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2026.201265_bib40","doi-asserted-by":"crossref","first-page":"e002899","DOI":"10.1136\/jitc-2021-002899","article-title":"Deregulation of HLA-I in cancer and its central importance for immunotherapy","volume":"9","author":"Hazini","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201265_bib41","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1002\/hem3.84","article-title":"Human leukocyte antigen (HLA) class I expression on Hodgkin-Reed-Sternberg cells is an EBV-independent major determinant of microenvironment composition in classic Hodgkin lymphoma","volume":"8","author":"M\u00fcller-Meinhard","year":"2024","journal-title":"HemaSphere"},{"key":"10.1016\/j.omton.2026.201265_bib42","first-page":"146","article-title":"Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes","volume":"1","author":"Nguyen-Van","year":"2011","journal-title":"Am J Blood Res"},{"key":"10.1016\/j.omton.2026.201265_bib43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ymthe.2020.09.011","article-title":"CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients","volume":"29","author":"Amini","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201265_bib44","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.ymthe.2020.06.002","article-title":"CRISPR-Cas9-Mediated Glucocorticoid Resistance in Virus-Specific T Cells for Adoptive T Cell Therapy Posttransplantation","volume":"28","author":"Kaeuferle","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201265_bib45","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ymthe.2025.01.009","article-title":"Depletion of alloreactive B cells by drug-resistant chimeric alloantigen receptor T cells to prevent transplant rejection","volume":"33","author":"Dragon","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201265_bib46","doi-asserted-by":"crossref","first-page":"e002516","DOI":"10.1136\/jitc-2021-002516","article-title":"Induction of EBV latent membrane protein-2A (LMP2A)-specific T cells and construction of individualized TCR-engineered T cells for EBV-associated malignancies","volume":"9","author":"Zhang","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201265_bib47","article-title":"Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors","volume":"7","author":"Kunert","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.omton.2026.201265_bib48","doi-asserted-by":"crossref","first-page":"10828","DOI":"10.3390\/ijms221910828","article-title":"Improving CAR T-Cell Persistence","volume":"22","author":"Pietrobon","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2026.201265_bib49","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1158\/1078-0432.CCR-06-0121","article-title":"Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer","volume":"12","author":"Robertson","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201265_bib50","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3390\/cancers12020375","article-title":"Design and Characterization of an \u201cAll-in-One\u201d Lentiviral Vector System Combining Constitutive Anti-G(D2) CAR Expression and Inducible Cytokines","volume":"12","author":"Zimmermann","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201265_bib51","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1158\/1078-0432.CCR-23-3157","article-title":"Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers","volume":"30","author":"Fischer-Riepe","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201265_bib52","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1146\/annurev.immunol.19.1.423","article-title":"Interleukin-18 regulates both Th1 and Th2 responses","volume":"19","author":"Nakanishi","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.omton.2026.201265_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.919973","article-title":"Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment","volume":"13","author":"Ihim","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201265_bib54","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1146\/annurev-immunol-042617-053352","article-title":"Signaling and Function of Interleukin-2 in T Lymphocytes","volume":"36","author":"Ross","year":"2018","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.omton.2026.201265_bib55","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12967-015-0460-x","article-title":"A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer","volume":"13","author":"Koneru","year":"2015","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omton.2026.201265_bib56","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1158\/2326-6066.CIR-19-0910","article-title":"Optimization of T-cell Receptor-Modified T Cells for Cancer Therapy","volume":"8","author":"Drakes","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omton.2026.201265_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202350413","article-title":"Bystander activation of tissue-resident memory CD4 T cells: Getting by with a little help from unfamiliar T-cell friends","volume":"53","author":"Cornelis","year":"2023","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.omton.2026.201265_bib58","first-page":"1","article-title":"The activation of bystander CD8(+) T cells and their roles in viral infection","volume":"51","author":"Kim","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.omton.2026.201265_bib59","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/s12276-020-00486-7","article-title":"Bystander CD4(+) T cells: crossroads between innate and adaptive immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.omton.2026.201265_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1465889","article-title":"Mechanisms governing bystander activation of T cells","volume":"15","author":"Yosri","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201265_bib61","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1002\/cncr.30541","article-title":"Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma","volume":"123","author":"Huang","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.omton.2026.201265_bib62","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s11864-013-0231-y","article-title":"EBV-related lymphomas: new approaches to treatment","volume":"14","author":"Kanakry","year":"2013","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.omton.2026.201265_bib63","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1200\/JCO.20.01709","article-title":"Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas","volume":"39","author":"Heslop","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201265_bib64","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.semcancer.2022.04.008","article-title":"Fibroblast heterogeneity in solid tumors: From single cell analysis to whole-body imaging","volume":"86","author":"Peltier","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.omton.2026.201265_bib65","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12967-020-02301-3","article-title":"High-intensity interval training in allogeneic adoptive T-cell immunotherapy - a big HIT?","volume":"18","author":"Heinemann","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omton.2026.201265_bib66","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.18632\/oncotarget.23531","article-title":"Personalized adoptive immunotherapy for patients with EBV-associated tumors and complications: Evaluation of novel naturally processed and presented EBV-derived T-cell epitopes","volume":"9","author":"Bieling","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2026.201265_bib67","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jim.2016.01.007","article-title":"Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-kappaB, NFAT and AP-1","volume":"430","author":"Jutz","year":"2016","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.omton.2026.201265_bib68","first-page":"3321","article-title":"Establishment of Epstein-Barr virus growth-transformed lymphoblastoid cell lines","author":"Hui-Yuen","year":"2011","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.omton.2026.201265_bib69","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/eji.202048599","article-title":"PAKC: A novel panel of HLA class I antigen presentation machinery knockout cells from the same genetic origin","volume":"51","author":"de Waard","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.omton.2026.201265_bib70","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ymthe.2005.08.012","article-title":"Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells","volume":"13","author":"Schambach","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201265_bib71","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1089\/hum.1995.6.9-1203","article-title":"Inducible, high-level production of infectious murine leukemia retroviral vector particles pseudotyped with vesicular stomatitis virus G envelope protein","volume":"6","author":"Yang","year":"1995","journal-title":"Hum. Gene Ther."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:35:45Z","timestamp":1790253345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926001414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2950329926001414"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201265","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation LMP2A-targeting TCR-recombinant T cells with inducible IL-18 expression to treat EBV-associated malignancies","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201265","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201265"}}